Trial intelligence / Profile preview

Oral versus intravenous palonosetron with dexamethasone for prevention of cisplatin-induced nausea and vomiting

2010-022223-29Phase 3Completed

Sponsor
Helsinn
Start
Feb 2011
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoint: Complete response during acute phase. Started Feb 2011; status: completed.

02

Drugs

palonosetron
03

Conditions

chemotherapy-induced nausea and vomiting (CINV)

Beyond the preview

Go deeper on 2010-022223-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022223-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call